Sign In

QOPI
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

FDA Approves Azacitidine For Newly Diagnosed Juvenile Myelomonocytic Leukemia

Oncology Practice Insider

Related

FDA Approves Dabrafenib With Trametinib For Pediatric Patients With Low-grade Glioma With a BRAF V600E Mutation
FDA Expands Early Breast Cancer Indication For Abemaciclib With Endocrine Therapy
FDA Grants Accelerated Approval to Pirtobrutinib For Relapsed or Refractory Mantle Cell Lymphoma
FDA Alerts

On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Read more.